Idiopathic membranous glomerulonephritis
disease diseaseOn this page
Also known as Extramembranous glomerulonephritisglomerulonephritis, membranousidiopathic membranous nephropathyMBNPmembranous GNmembranous nephropathy - Idiopathicmembranous nephropathy, susceptibility toMGN
Summary
Idiopathic membranous glomerulonephritis (MONDO:0013860) is a disease and 52 clinical trials. Top therapeutic interventions include mycophenolate mofetil, belimumab, and tacrolimus anhydrous. A subtype of membranous glomerulonephritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 1
- Clinical trials: 52
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | 1-9 / 1 000 000 | 0.8103 | Worldwide | Validated |
| Annual incidence | 1-9 / 1 000 000 | 0.9194 | Europe | Validated |
Signs & symptoms
Clinical features (HPO)
1 HPO clinical features (Orphanet curated; top 1 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0034002 | Anti-phospholipase A2 receptor antibody positivity | Frequent (30-79%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | idiopathic membranous glomerulonephritis |
| Mondo ID | MONDO:0013860 |
| OMIM | 614692 |
| Orphanet | 97560 |
| NCIT | C123060 |
| SNOMED CT | 722119002 |
| UMLS | C0086445 |
| MedGen | 39226 |
| GARD | 0009180 |
| Is cancer (heuristic) | no |
Also known as: Extramembranous glomerulonephritis · glomerulonephritis, membranous · idiopathic membranous nephropathy · MBNP · membranous GN · membranous nephropathy - Idiopathic · membranous nephropathy, susceptibility to · MGN
Disease family
This is a subtype of membranous glomerulonephritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › nephritis › glomerulonephritis › membranous glomerulonephritis › idiopathic membranous glomerulonephritis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 52.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 25 |
| PHASE3 | 9 |
| PHASE4 | 6 |
| PHASE2 | 6 |
| PHASE2/PHASE3 | 3 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05839314 | PHASE4 | RECRUITING | Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy |
| NCT07404436 | PHASE4 | RECRUITING | Rivaroxaban in Idiopathic Membranous Nephropathy |
| NCT00843856 | PHASE4 | COMPLETED | Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis |
| NCT01129557 | PHASE4 | TERMINATED | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease |
| NCT01386554 | PHASE4 | COMPLETED | Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients |
| NCT03170323 | PHASE4 | UNKNOWN | Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy |
| NCT04745728 | PHASE3 | RECRUITING | Different Immunosuppressive Treatment in iMN |
| NCT05914155 | PHASE3 | RECRUITING | Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome |
| NCT00135954 | PHASE3 | COMPLETED | Treatment of Patients With Idiopathic Membranous Nephropathy |
| NCT00135967 | PHASE2/PHASE3 | COMPLETED | Mycophenolate Mofetil in Membranous Nephropathy |
| NCT00362531 | PHASE2/PHASE3 | COMPLETED | Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome |
| NCT00404794 | PHASE3 | COMPLETED | A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis |
| NCT00404833 | PHASE3 | COMPLETED | Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental |
| NCT01180036 | PHASE2/PHASE3 | COMPLETED | MEmbranous Nephropathy Trial Of Rituximab |
| NCT01282073 | PHASE3 | COMPLETED | Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy |
| NCT01508468 | PHASE3 | COMPLETED | Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy |
| NCT03018535 | PHASE3 | UNKNOWN | Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy |
| NCT04743739 | PHASE3 | TERMINATED | Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN |
| NCT00694863 | PHASE2 | COMPLETED | Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy |
| NCT01610492 | PHASE2 | COMPLETED | A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy |
| NCT01762852 | PHASE2 | WITHDRAWN | Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy |
| NCT02173106 | PHASE2 | UNKNOWN | A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy |
| NCT03804359 | PHASE2 | COMPLETED | Personalized Medicine for Membranous Nephropathy |
| NCT04145440 | PHASE1/PHASE2 | COMPLETED | Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) |
| NCT04154787 | PHASE2 | TERMINATED | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy |
| NCT00805753 | PHASE1 | COMPLETED | Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy |
| NCT07423572 | EARLY_PHASE1 | NOT_YET_RECRUITING | Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) |
| NCT00199628 | Not specified | COMPLETED | Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization |
| NCT00302523 | Not specified | COMPLETED | Tacrolimus Treatment of Patients With Idiopathic Membranous Nephropathy |
| NCT01093781 | Not specified | WITHDRAWN | Aliskiren in Patients With Idiopathic Membranous Nephropathy |
| NCT01161459 | Not specified | COMPLETED | Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid |
| NCT01799460 | Not specified | UNKNOWN | Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy |
| NCT01845688 | Not specified | COMPLETED | Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy |
| NCT02610595 | Not specified | UNKNOWN | Study on the Therapeutic Effect of TCM Treatment for MDR MN |
| NCT03466801 | Not specified | TERMINATED | The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I. |
| NCT03475602 | Not specified | TERMINATED | Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy |
| NCT03549663 | Not specified | UNKNOWN | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN) |
| NCT03864250 | Not specified | UNKNOWN | Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy |
| NCT03880643 | Not specified | COMPLETED | Rituximab in Refractory Primary Membranous Nephropathy |
| NCT04498962 | Not specified | UNKNOWN | The Effect of Danzhu Fuyuan Granule as Adjunctive Therapy for Chronic Stable Angina, Vascular Dementia and Idiopathic Membranous Nephropathy: A Bayesian Basket Trial |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| MYCOPHENOLATE MOFETIL | 4 | 5 |
| BELIMUMAB | 4 | 2 |
| TACROLIMUS ANHYDROUS | 4 | 2 |
| ALISKIREN | 4 | 1 |
| ANGIOTENSIN II | 4 | 1 |
| CHLORAMBUCIL | 4 | 1 |
| CORTICOTROPIN | 4 | 1 |
| COSYNTROPIN | 4 | 1 |
| CYCLOSPORINE | 4 | 1 |
| IPTACOPAN | 4 | 1 |
| RIVAROXABAN | 4 | 1 |
| VALSARTAN | 4 | 1 |
| WARFARIN SODIUM | 4 | 1 |
| FELZARTAMAB | 3 | 1 |
| CHEMBL4564923 | 0 | 1 |
| CHEMBL115622 | 0 | 1 |
| CHEMBL406352 | 0 | 1 |